annb0t
Top 20
Mesoblast Limited
NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and financial results for the period ended March 31, 2023.
OPERATIONAL HIGHLIGHTS
Remestemcel-L BLA filing accepted by FDA, PDUFA goal date set
US Food and Drug Administration (FDA) accepted Mesoblastâs filing of the Biologics License Application (BLA) for remestemcel-L in th...
>>> Read more: Mesoblast Reports Operational and Financial Highlights for Quarter Ended March 31, 2023
NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and financial results for the period ended March 31, 2023.
OPERATIONAL HIGHLIGHTS
Remestemcel-L BLA filing accepted by FDA, PDUFA goal date set
US Food and Drug Administration (FDA) accepted Mesoblastâs filing of the Biologics License Application (BLA) for remestemcel-L in th...
>>> Read more: Mesoblast Reports Operational and Financial Highlights for Quarter Ended March 31, 2023
